APRIL based therapeutic strategies to target BCMA and TACI in multiple myeloma
Myeloma remains largely incurable and there is an unmet need for new therapies. B-cell maturation antigen (BCMA) is an attractive therapeutic target due to its restricted expression on normal and malignant plasma cells(PC). A natural ligand for BCMA is a proliferating ligand (APRIL) which also natur...
Main Author: | Lee, L. S. H. |
---|---|
Published: |
University College London (University of London)
2017
|
Subjects: | |
Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.724624 |
Similar Items
-
The role of APRIL in promoting cell cycle progression and drug resistance in multiple myeloma
by: Quinn, J.
Published: (2013) -
Immune suppression in multiple myeloma : strategies to overcome NK cell inhibition
by: Giunti, Giulia
Published: (2014) -
Prognostic factors in paraproteinaemia, treatment of multiple myeloma
by: Al-Rubei, Kastal J.
Published: (1980) -
Enhancement of death receptor-mediated apoptosis in multiple myeloma cells
by: Arhoma, Amal Ali
Published: (2017) -
A study of c-myc translational regulation in multiple myeloma
by: Paulin, Fiona E. M.
Published: (1997)